1Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein[gamma] selective modulator. Mol Endocrinol, 2003,17:662-676. 被引量：1
2Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med,2002,8:731-737. 被引量：1
3Czoski Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess, 2004,8:1 91. 被引量：1
4Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinicaI trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care,2002,25:815 821. 被引量：1
5Hansen AM, Christensen IT, Hansen Jg, et al. Differential interactions of nateglinide and rapaglinide on the human betacell sulphonylurea receptor-1. Diabetes, 2002,51:2789-2795. 被引量：1
6Keilson L, Mather S, Waiter YH, et al. Synergistic effects of nateglinide and meal administration in patients with type 2diabetes mellitus. J Clin Endocrinol Metab, 2000,85:1081-1086. 被引量：1
7Owens DR. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Eur J Clin Invest,1999,29(suppl 2) : S30-S37. 被引量：1
8Bragne J, V lund AA. Insulin analogues with improved pharmacokinetic profiles. Adv Drug Deliv Rev, 1999,35:307-335. 被引量：1
9Anderson JH, Brunelle RL, Koivisto VA, et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther, 1997,19:62-72. 被引量：1
10Glazer B, Zalani S, Symanowski SM, et al. The cardiovascular safety profile of insulin lispro(LP). Diabetologia , 1997,40(suppl 1) :A351. 被引量：1
5Hansen AM, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and rapaglinide on the human beta - cell sulphonylurea receaptor - 1. Diabetes 2002, 51:2789 - 2795. 被引量：1
6Keilson L, Mather S, Walter YH, et al. Synergistic effects of nateglinide and meal administration in patients with type 2 diabetes mellitus. J clin Endcrinol Metab 2000, 85:1081 - 1086. 被引量：1
7Stevens RJ, Coleman RL, Adler, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes.Diabetes Care 2004 ,27:201 - 207. 被引量：1
8Nathan DM, lachin J, Cleary P, et al. Intensive diabetes therapy and carotia intima- media thickness in type 1 diabetes mellitus. N Engl J Med 2003,348:2294- 2303. 被引量：1
10Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes study. Diabetes Care 1999, 22 : 920 -924. 被引量：1
